How ABT-263 rejuvenates wound healing capacity in aged skin
Aged skin heals more slowly. That has long been known. But a new experiment shows that removing damaged cells can significantly speed up that process.
Researchers tested ABT-263, a compound that selectively removes cells that have stopped dividing (senescent cells). These cells accumulate with age and impair tissue repair. In old mice, wounds were treated with ABT-263 applied topically as a cream. The result: wounds healed considerably faster than in untreated animals.
The study also shows that ABT-263 activates genes involved in collagen production and tissue regeneration. This suggests that the compound does not merely remove cells but also actively triggers repair processes.
Senescent cells as a brake on healing
Senescent cells are not inert byproducts. They secrete substances that influence surrounding cells and sustain inflammatory responses. The more senescent cells are present, the less room there is for new, healthy cells to grow. In aged skin, that effect is clearly visible in slower wound closure.
ABT-263 belongs to the class of senolytics: compounds that specifically target senescent cells. Earlier research tested these substances mainly via injection or oral administration. The new topical approach is interesting because it works locally and limits systemic side effects.
From mice to humans: still a long road
The results are promising, but the research was conducted in mice. Translation to humans is not straightforward. Human skin differs substantially from mouse skin in thickness, cell composition and repair mechanisms. Moreover, ABT-263 was originally developed as a cancer drug and has known side effects at higher doses.
Even so, the study points in an interesting direction. If senolytics can be applied locally without systemic effects, that opens the door to applications in people with slow wound healing, such as older adults or patients with diabetes.